The financials
UroGen Pharma Ltd. by the numbers
UroGen Pharma Ltd. (URGN) reported revenue of $51M in Q1 2026 (quarter ended March 31, 2026), up 152% from the same quarter a year earlier. That came with a gross margin of 92% and net loss of $24M. For the full year FY2025, revenue was $110M (+21% year on year) and net income −$153M. Its largest product in 2026-Q1 was Zusduri at $29M, 57% of the disclosed total, just ahead of Jelmyto at 43%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $51M | $20M | +152% |
| Gross profit | $47M | $18M | +161% |
| Operating income | −$20M | −$37M | n/a |
| Net income | −$24M | −$44M | n/a |
| Product | Revenue | Share |
|---|---|---|
| Zusduri | $29M | 57% |
| Jelmyto | $22M | 43% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $51.0M (+85%)
Jelmyto grew +7.2% year on year
Segment Latestquarter on quarteryear on year
- Zusduri$29.2M$29.2MQoQ +1544%year on year -+1544%-
- Jelmyto$21.7M$21.7MQoQ -16%year on year +7.2%-16%+7.2%